For the month ended 31 July 2026, Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) reported no changes in its share capital structure, according to the company’s Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 3 August 2026.
• Authorised share capital remained at 10.00 billion ordinary shares with a par value of HKD 0.0001 each, equivalent to authorised capital of HKD 1.00 million. No increase or decrease was recorded during the month.
• Issued share capital was unchanged at 2,032,890,585 ordinary shares. The company held no treasury shares, and there were no allotments, cancellations, or repurchases in July.
• Sinco Pharma confirmed compliance with the Main Board’s minimum public-float requirement of 25%, indicating sufficient free-float liquidity.
• The company reported zero movements under its share option scheme adopted on 26 May 2025. As of end-July, up to 203.29 million shares remain available for potential future grants, with no options currently outstanding or exercised.
• No warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding during the reporting period.
In summary, Sinco Pharma’s capital structure and share count were static through July 2026, with full adherence to Hong Kong listing requirements and no fundraising or dilution activities recorded for the month.
Comments